These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 8792690)

  • 1. Comparative efficacy of a high or low dose of interferon alpha 2b in chronic hepatitis C: a randomized controlled trial.
    Tassopoulos NC; Karvountzis G; Touloumi G; Delladetsima JK; Papatheodoridis GV; Katsoulidou A; Retalis G; Hatzakis A
    Am J Gastroenterol; 1996 Sep; 91(9):1734-8. PubMed ID: 8792690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
    Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
    Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic hepatitis C with interferon-alpha. Clinical histological and virological implications.
    Olaso V; Córdoba J; Berenguer M; Prieto M; Lainez B; Argüello L; Valverde J; Pascual S; Gobernado M; Berenguer J
    Rev Esp Enferm Dig; 1997 Jul; 89(7):531-50. PubMed ID: 9265839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled study to determine the optimal dose regimen of interferon-alpha 2b in chronic hepatitis C.
    Hakozaki Y; Shirahama T; Katou M; Nakagawa K; Oba K; Mitamura K
    Am J Gastroenterol; 1995 Aug; 90(8):1246-9. PubMed ID: 7639224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
    Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G
    Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. alpha-Interferon retreatment of patients with chronic hepatitis C.
    Rabinovitz M; Block G; Finkelstein SD
    Am J Gastroenterol; 1996 Aug; 91(8):1523-6. PubMed ID: 8759654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Value of high-dose interferon-alpha in chronic viral hepatitis C patients non-responder to a 1st treatment. Pilot study prospective and randomized trial].
    Rolachon A; Kézachian G; Causse X; Baud M; Leroy V; Maynard-Muet M; Pasquier D; Zarski JP
    Gastroenterol Clin Biol; 1997; 21(12):924-8. PubMed ID: 9587555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF.
    Van Thiel DH; Faruki H; Friedlander L; Fagiuoli S; Caraceni P; Molloy PJ; Kania RJ; Wright HI
    Hepatogastroenterology; 1995; 42(6):907-12. PubMed ID: 8847044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical and virological response of chronic hepatitis C after treatment with interferon-alpha for 6 or 12 months: predictors of sustained remission.
    Papatheodoridis GV; Katsoulidou A; Touloumi G; Delladetsima JK; Hatzakis A; Tassopoulos NC
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):469-75. PubMed ID: 8804876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved sustained response following treatment of chronic hepatitis C by gradual reduction in the interferon dose.
    Shiffman ML; Hofmann CM; Luketic VA; Sanyal AJ; Contos MJ; Mills AS
    Hepatology; 1996 Jul; 24(1):21-6. PubMed ID: 8707264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term prognosis of chronic hepatitis C after treatment with interferon alpha 2b and characterization of incomplete responders.
    Hakozaki Y; Shirahama T; Katou M; Nakagawa K; Oba K; Yoshii O; Matsumoto T; Kuwabara N; Mitamura K
    Am J Gastroenterol; 1996 Oct; 91(10):2144-9. PubMed ID: 8855738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
    Weiland O; Chen M; Lindh G; Mattsson L; Schvarcz R; Sönnerborg A; Wahl M; Wejstål R; Widell A; Norkrans G
    Scand J Infect Dis; 1995; 27(5):319-24. PubMed ID: 8588128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic relevance of hepatitis C virus genotype for responsiveness to interferon-alpha].
    Berg T; König V; Küther S; Heuft HG; Wittmann G; Lobeck H; Hopf U
    Z Gastroenterol; 1995 Aug; 33(8):426-30. PubMed ID: 7483733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of interferons in treating children with chronic hepatitis C.
    Matsuoka S; Mori K; Nakano O; Yuasa Y; Taguchi Y; Hayabuchi Y; Kuroda Y
    Eur J Pediatr; 1997 Sep; 156(9):704-8. PubMed ID: 9296534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A comparative randomized controlled study of the efficacy of interferon alfa-2b and interferon alfa-2a in the treatment of chronic hepatitis C].
    Fernández I; Castellano G; Canga F; Colina F; García H; Fuertes A; Casis B; Martín A; Solís JA
    Gastroenterol Hepatol; 1995 Feb; 18(2):66-72. PubMed ID: 7621277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow-up of 211 patients.
    Manesis EK; Papaioannou C; Gioustozi A; Kafiri G; Koskinas J; Hadziyannis SJ
    Hepatology; 1997 Sep; 26(3):734-9. PubMed ID: 9303505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of recombinant interferon alpha 2a in the treatment of chronic hepatitis C: a randomized prospective study comparing two dose schedules in Chinese patients.
    Yao G; Ji Y; Yang M; Xu D; Gao J; Wu X; Zhang Q; Hu D
    Chin Med J (Engl); 1998 Oct; 111(10):922-6. PubMed ID: 11189241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of daily administration period of natural alpha-interferon in patients with chronic hepatitis C.
    Toyoda H; Nakano S; Kumada T; Takeda I; Sugiyama K; Osada T; Kiriyama S
    Am J Gastroenterol; 1996 Apr; 91(4):743-7. PubMed ID: 8677941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective comparison of four lymphoblastoid interferon alpha schedules for chronic hepatitis C. A multivariate analysis of factors predictive of sustained response to treatment.
    Bellobuono A; Mondazzi L; Tempini S; Silini E; Idéo G
    Eur J Gastroenterol Hepatol; 1997 Dec; 9(12):1169-77. PubMed ID: 9471022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of alcohol intake on the efficacy of interferon therapy in patients with chronic hepatitis C as evaluated by multivariate logistic regression analysis.
    Mochida S; Ohnishi K; Matsuo S; Kakihara K; Fujiwara K
    Alcohol Clin Exp Res; 1996 Dec; 20(9 Suppl):371A-377A. PubMed ID: 8986241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.